Viking Therapeutics (LTS:0VQA) Change In Receivables : $3.01 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Viking Therapeutics Change In Receivables?

Viking Therapeutics's change in receivables for the quarter that ended in Mar. 2025 was $2.47 Mil. It means Viking Therapeutics's Accounts Receivable declined by $2.47 Mil from Dec. 2024 to Mar. 2025 .

Viking Therapeutics's change in receivables for the fiscal year that ended in Dec. 2024 was $1.20 Mil. It means Viking Therapeutics's Accounts Receivable declined by $1.20 Mil from Dec. 2023 to Dec. 2024 .

Viking Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Viking Therapeutics's liquidation value for the three months ended in Mar. 2025 was $831.78 Mil.

Viking Therapeutics Change In Receivables Historical Data

The historical data trend for Viking Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viking Therapeutics Change In Receivables Chart

Viking Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

2.59

1.18

0.61

0.32

1.20

Viking Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															0.66	-0.16	1.35	-0.65	2.47

Viking Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.01 Mil.

Viking Therapeutics (LTS:0VQA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Viking Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Viking Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Viking Therapeutics's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	851.858	-	20.075	+	0.75 * 0	+	0.5 * 0
=	831.78

Viking Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Viking Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Viking Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (LTS:0VQA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

VKTX:USA 1VT:Germany 1VT:Germany

Address

9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121

Website

https://www.vikingtherapeutics.com

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Viking Therapeutics Headlines

No Headlines